Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) reported positive results from a
Phase 3 clinical trial of oral telotristat etiprate to treat cancer
patients with carcinoid syndrome. The stock price jumped $5.16 to $13.60.
Positive trial results for Lexicon Pharmaceuticals
August 03, 2015 at 14:02 PM EDT
